Qianyuan Pharma

Qianyuan Pharma is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics for autoimmune and inflammatory diseases. The company's research focuses on high-selectivity kinase inhibitors, aiming to provide safer and more effective oral treatment options. Its lead asset, QY-201, is a dual inhibitor of Tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), currently undergoing Phase 2 clinical trials for moderate-to-severe psoriasis and atopic dermatitis. Qianyuan Pharma is also exploring the potential of QY-201 in other indications such as ulcerative colitis. The company has secured significant funding from top-tier investors, including Hillhouse Capital and Matrix Partners China, to accelerate its clinical programs. Qianyuan Pharma aims to address the substantial unmet medical needs in the global immunology market through its robust drug discovery engine.